| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Alifedrine targets beta-adrenergic receptors (β-AR). As a partial beta-adrenergic agonist, it binds to and partially activates β-adrenergic receptors, leading to increased intracellular cAMP levels through the activation of adenylyl cyclase. This results in positive inotropic effects (increased cardiac contractility) and may be beneficial in treating congestive heart failure.
|
|---|---|
| ln Vitro |
In vitro, Alifedrine shows agonist activity at beta-adrenergic receptors. It stimulates cAMP accumulation in cells expressing β₁ or β₂ receptors. As a partial agonist, it produces a submaximal response compared to full agonists such as isoproterenol. Specific EC50 values for receptor activation are not detailed in the available literature.
|
| ln Vivo |
In vivo, Alifedrine is a cardiotonic agent with sympathomimetic properties. It may be used to treat congestive heart failure by increasing cardiac contractility through beta-adrenergic receptor activation. The compound's partial agonist activity may provide inotropic support with a reduced risk of excessive stimulation. Detailed pharmacokinetic and efficacy data are limited in the available literature.
|
| Enzyme Assay |
Beta-adrenergic receptor binding affinity is assessed using radioligand binding assays with [³H]-dihydroalprenolol or [¹²⁵I]-iodocyanopindolol as tracers. Membrane preparations from cells expressing β₁ or β₂ receptors are incubated with varying concentrations of Alifedrine and a fixed concentration of radioligand. Non-specific binding is determined using propranolol. After incubation at 25°C for 60-90 minutes, bound and free radioligands are separated by filtration. Ki values are calculated from competition curves.
|
| Cell Assay |
For functional assays, cells expressing β₁ or β₂ receptors are seeded in 96-well plates and treated with Alifedrine at varying concentrations. cAMP accumulation is measured by ELISA or by using a cAMP-responsive reporter gene. EC50 values for receptor activation are calculated from dose-response curves. To determine partial agonist activity, the maximal response of Alifedrine is compared to that of a full agonist such as isoproterenol.
|
| Animal Protocol |
For in vivo efficacy studies, animal models of heart failure (e.g., rats with coronary artery ligation or doxorubicin-induced cardiomyopathy) are used. Alifedrine is administered intravenously or orally at doses of 0.1-5 mg/kg. Cardiac function is assessed by echocardiography or by measuring left ventricular pressure and contractility (dP/dt max). Heart rate and blood pressure are monitored. For pharmacokinetic studies, blood samples are collected and plasma concentrations are measured by LC-MS/MS.
|
| Molecular Formula |
C18H27NO2
|
|---|---|
| Molecular Weight |
289.41248
|
| Exact Mass |
289.204
|
| CAS # |
78756-61-3
|
| Related CAS # |
72913-80-5 (HCl);78756-61-3;
|
| PubChem CID |
51719
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.064g/cm3
|
| Boiling Point |
438ºC at 760 mmHg
|
| Flash Point |
218.7ºC
|
| Index of Refraction |
1.537
|
| LogP |
3.628
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
21
|
| Complexity |
306
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(C(C1=CC=CC=C1)O)NCCC(=O)C2CCCCC2
|
| InChi Key |
UEELVIXXTBPOCF-KSSFIOAISA-N
|
| InChi Code |
InChI=1S/C18H27NO2/c1-14(18(21)16-10-6-3-7-11-16)19-13-12-17(20)15-8-4-2-5-9-15/h3,6-7,10-11,14-15,18-19,21H,2,4-5,8-9,12-13H2,1H3/t14-,18-/m0/s1
|
| Chemical Name |
1-cyclohexyl-3-[[(1R,2S)-1-hydroxy-1-phenylpropan-2-yl]amino]propan-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4553 mL | 17.2765 mL | 34.5531 mL | |
| 5 mM | 0.6911 mL | 3.4553 mL | 6.9106 mL | |
| 10 mM | 0.3455 mL | 1.7277 mL | 3.4553 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
